MedTrace Logo

Serum Endostatin Type 2 Diabetic Patients

NCT03404037 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 110

Last updated 2018-01-19

No results posted yet for this study

Summary

To assess the relationship between serum endostatin (ES) and Coronary artery calcification (CAC) in type 2 diabetic (T2DM) patients.

Conditions

Interventions

DIAGNOSTIC_TEST

serum endostatin level

An oral (metoprolol 20 mg) was given to the patients with heart rates \> 60 beats/minute and had no contraindications to beta-blockers, one hour before the scan. Sublingual nitroglycerin was given to all patients before CT examination. A 64-slice CT scanner (Sensation 64; Siemens Medical System, Germany) was used for imaging all subjects. All CT examinations were done during inspiratory breath holding. Endostatin levels were measured using a sandwich ELISA kit according to the manufacturer's instructions endostatin ELISA kit (R\&D Systems, Minneapolis, Minnesota, USA

Sponsors & Collaborators

  • Zagazig University

    lead OTHER_GOV

Principal Investigators

  • Hazem M Elashmawy, MD. Msc · Faculty of medicine, Zagazig University

Eligibility

Min Age
50 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-02
Primary Completion
2017-11-11
Completion
2017-12-20

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03404037 on ClinicalTrials.gov